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she primary goals of treatment for patients with stable
chronic) coronary artery disease (CAD) include the pre-
ention of death and myocardial infarction (MI) and the
elief of ischemic symptoms. In this regard, medical therapy
nd revascularization comprise complementary approaches.
espite the dissemination of evidence-based practice guide-
ines (1–3) and appropriate use criteria (4), there is wide-
pread recognition that clinical decision-making varies con-
iderably among physicians, practice groups, and health
ystems, particularly with respect to the threshold at which
ercutaneous coronary intervention (PCI) is undertaken. As
n example, in an observational cohort study of 2004
edicare beneficiaries, less than one-half (44.5%) under-
ent stress testing in the 90 days before elective PCI (5).
here is equal concern that the intensity and scope of
edical therapy are often not accorded the attention they
eserve. The reasons for these discrepancies are some-
imes embedded in the context of an individual patient’s
linical course and its dynamic change. Certainly, no one
ize fits all. Several lines of evidence, however, suggest
hat opportunities remain to narrow the gap between
ecommended and applied management strategies for
atients with chronic CAD.
See page 1348
In the more than 2 years since publication of its main
esults, the COURAGE (Clinical Outcomes Utilizing Re-
ascularization and Aggressive Drug Evaluation) trial has
een the subject of intense scrutiny and editorial comment
6–8). That there was no difference in the primary com-
osite outcome (death from any cause and nonfatal MI)
etween patients assigned to an initial strategy of percuta-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Cardiovascular Division, Department of Medicine, Brigham and
omen’s Hospital, Harvard Medical School, Boston, Massachusetts. Dr. O’Garav
s the chair of the Data Monitoring Committee of Lantheus Medical Imaging,
nd is a consultant for E-Valve.eous coronary intervention with optimal medical therapy
PCI  OMT) and those assigned to OMT had been
onsistently observed in other, smaller trials of this nature
9). There were also no significant differences between
roups for the secondary composite end point of death, MI,
nd stroke; for hospital stay for acute coronary syndrome;
nd for MI. However, nearly one-third of patients in the
MT group required revascularization for clinical indica-
ions over the course of follow-up, and patients who
nderwent PCI initially reported better angina-specific
ealth status and quality of life over the first 6 to 24 months
f the study, differences that were no longer apparent at 3
ears (10). A small substudy of the COURAGE trial
uggested that PCI might provide relatively greater reduc-
ion in ischemic burden (11), an observation that merits
urther study.
The observed event rates in the COURAGE trial were
ubstantially lower than predicted, due in part to the excellent
ackground therapy provided to the study participants. Inter-
stingly, the major outcomes in the COURAGE trial were
imilar to those reported in the EuroHeart Survey for a
ubgroup of patients with stable angina and angiographi-
ally confirmed CAD (rate of death or nonfatal MI 3.9 per
00 patient-years) (12). Overestimation of clinical event
ates in medically managed patients has been observed in
ecent post-MI and acute coronary syndrome trials (13,14).
he implication is clear that the aggressive medical and
ifestyle interventions employed in such trials are effective
nd safe for large numbers of patients across the CAD
pectrum. Whether they can be implemented in routine
linical practice, outside the confines of a well-executed
linical trial, remains to be seen.
In this issue of the Journal, the COURAGE investigators
escribe in greater detail the components of the multimo-
ality treatment program used for both the PCI and OMT
roups, adherence rates observed over the course of the trial,
nd the targets achieved (15). It is self-evident that the
emarkable results seen across multiple domains were in no
mall measure related to regularly scheduled nurse manager
isits and the provision of most medications (including
s
c
e
d
m
r
s
n
i
c
i
p
p
T
p
p
s
r
t
b
w
p
c
u
h
r
c
i
c
r
m
c
(
e
m
n
a
a
w
C
i
p
a
s
c
w
p
h
d
A
a
t
t
r
t
s
o
t
C
s
f
p
p
a
f
t
p
w
a
a
R
C
W
B
R
1360 O’Gara JACC Vol. 55, No. 13, 2010
The COURAGE Trial: Can We Deliver on Its Promise? March 30, 2010:1359–61tatins, clopidogrel, beta-blockers, and either angiotensin-
onverting enzyme inhibitors or angiotensin receptor block-
rs) at no cost to the patient. The degree to which patient
emographics (85% male, 86% white, 42% U.S. veterans)
ight have influenced the results is unclear. The adherence
ates observed for the use of evidence-based medications for
econdary prevention and ischemia management establish a
ew benchmark for patients with chronic CAD. Significant
mprovements were noted for smoking cessation, dietary
omposition, and physical activity levels, yet body mass
ndex increased slightly, the hemoglobin A1c levels of
atients with diabetes at baseline did not change, and 8% of
atients developed diabetes over the course of the study.
he blood pressure and lipid levels achieved were exem-
lary, although 30% to 40% of patients did not meet the
re-specified targets of 130 mm Hg systolic blood pres-
ure and 85 mg/dl for low-density lipoprotein cholesterol,
espectively, despite the disciplined manner in which pa-
ients were managed. Lastly, there were no differences
etween the PCI and OMT groups in the intensity with
hich the interventions were applied, the (surrogate) end
oints achieved, or treatment satisfaction scores.
The COURAGE trial reinforces several important con-
epts. Treatment programs that incorporate multi- versus
ni-modality interventions are more likely to improve ad-
erence rates (16). Prior work has established a plausible
elationship between adherence and outcomes for several
ardiovascular conditions and in several clinical settings,
ncluding hypertension, chronic CAD, heart failure, dis-
harge after MI, and after PCI (17–21). Nonadherence can
elate to patient (age, race), condition (depression), treat-
ent (complexity), health system (fragmentation), and so-
ioeconomic (cost) factors, either singly or in combination
22). The COURAGE trial was designed to lessen or
liminate the impact of several of these factors. Case
anagement or chronic care supervision coordinated by
urses, 1 of several mechanisms to reduce fragmentation
nd identify modifiable patient-specific conditions, has had
salutary effect on both adherence and outcomes in patients
ith heart failure, chronic CAD, or at high risk for incident
V events (23). Adherence to prescribed medications varies
nversely with the cost borne by the patient. Reductions in
harmacy benefits have been shown to result in lower
dherence rates. Choudry et al. (24) have shown in a
imulated Markov model that providing Medicare benefi-
iaries with free medications at time of discharge after MI
ould improve survival and save money from a societal
erspective.
With very rare exception, individual practice groups and
ealth care systems are not currently structured or financed to
eliver the intensity of longitudinal care provided to COUR-
GE trial enrollees (15,25). Several barriers will need to be
ddressed and overcome, ranging from workforce shortages
o the low prevalence of integrated health information
echnology platforms, drug cost, complexity of treatment
egimens, patient education/empowerment, disparities, cul-ural competence, and reimbursement. The current battles
urrounding health care reform do not engender much
ptimism, despite the emphasis on prevention in some of
he proposed legislation. It would be easy to dismiss the
OURAGE trial results as being too impractical, expen-
ive, or difficult to replicate in practice, were it not for the
act that this is precisely the direction in which multiple
rograms for quality and performance improvement have
ointed. It is also relevant to underscore the recognition that
pproximately one-half of the recent decline in U.S. deaths
rom coronary heart disease might be attributable to reduc-
ions in major risk factors (26). Implementation will require
olicymakers to make difficult but informed choices about
hat can be done to improve the public health in ways that
re both predictable and affordable from patient-centered
nd societal perspectives.
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